NECTAR LIFESCIENCE share price has zoomed 8% and is presently trading at Rs 41.5.
Meanwhile, the BSE HEALTHCARE index is at 42,404.8 (up 0.6%).
Among the top gainers in the BSE HEALTHCARE index today are Jubilant Pharmova (up 3.1%) and Pfizer (up 2.5%).
ASTER DM HEALTHCARE (down 0.8%) and POLY MEDICURE (down 0.6%) are among the top losers today.
Over the last one year, NECTAR LIFESCIENCE has moved up from Rs 25.5 to Rs 41.5, registering a gain of Rs 16.0 (up 62.7%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,099.5 to 42,404.8, registering a gain of 50.9% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 130.8%), Glenmark Pharma (up 125.5%) and SUVEN PHARMACEUTICALS (up 110.2%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,655.3 (down 0.1%).
The top losers among the BSE Sensex today are JSW Steel (down 1.2%) and Kotak Bank (down 0.8%). The most traded stocks in the BSE Sensex are Tata Steel and HCl Tech..
In the meantime, NSE Nifty is at 24,995.9 (down 0.1%). BPCL and Shriram Transport are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,433.3 to 81,655.3, registering a gain of 16,222.0 points (up 24.8%).
NECTAR LIFESCIENCE net profit grew 63.1% YoY to Rs 30 million for the quarter ended June 2024, compared to a profit of Rs 18 million a year ago. Net sales declined 8.8% to Rs 3,593 million during the period as against Rs 3,941 million in April-June 2023.
For the year ended March 2024, NECTAR LIFESCIENCE reported 120.7% increase in net profit to Rs 50 million compared to net loss of Rs 242 million during FY23. Revenue of the company grew 10.9% to Rs 14,423 million during FY24.
The current Price to earnings ratio of NECTAR LIFESCIENCE, based on rolling 12 month earnings, stands at 151.5.
Equitymaster requests your view! Post a comment on "NECTAR LIFESCIENCE Gains 8%; BSE HEALTHCARE Index Up 0.6%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!